Email this article EVALUATION OF THE SUBPOPULATION COMPOSITION OF CD34+ PLURIPOTENT HEMATOPOIETIC STEM CELLS IN BLOOD CANCERS
- Authors: Pashkina E.A.1, Aktanova A.A.1, Bykova M.V.1, Skachkov I.P.1, Pronkina N.V.1, Denisova V.V.1, Kozlov V.A.1
-
Affiliations:
- Federal State Budgetary Scientific Institution "Research Institute of Fundamental and Clinical Immunology", Laboratory of Clinical Immunopathology
- Section: Immunological readings in Chelyabinsk
- Submitted: 30.03.2025
- Accepted: 11.05.2025
- URL: https://rusimmun.ru/jour/article/view/17198
- DOI: https://doi.org/10.46235/2220-7619-EOT-17198
- ID: 17198
Cite item
Full Text
Abstract
Abstract
Introduction. Over the past decades, the incidence of malignant blood diseases has been steadily increasing. Unlike many other types of malignant neoplasms, blood cancers often occur at a young age, and are also the main cause of death among all pathologies of the hematopoietic tissue in pediatric patients. The cause of blood cancers is a mutation process in hematopoietic stem cells, which subsequently leads to an increase in the number of tumor clones and the displacement of healthy cells in the niches they occupy, which leads to a number of changes in the blood and bone marrow, including irreversible ones.
The aim of this study was to assess the subpopulation composition of pluripotent hematopoietic stem cells in patients with blood cancers and healthy donors. Materials and methods. The study included patients blood cancers (n = 13), including patients with acute lymphoblastic leukemia (ALL) n=3, acute myeloid leukemia (AML) n=3 and patients with multiple myeloma (MM) n=7, and healthy donors (n = 4). The phenotypic composition of hematopoietic CD34+CD38- pluripotent cells was assessed by flow cytometry using the following monoclonal antibodies: CD34 APC (BioLegend, USA), CD38 PE-Cy7 (ElabScience, China), CD45RA PerCP (ElabScience, China), CD90 APC-Cy7 (Cloud-Clone Corp., USA), Lin- (cocktail CD3/14/16/19/20/56) FITC (BioLegend, USA). The following populations were assessed: hematopoietic stem cells (Lin-CD34+CD38-CD45RA-CD90+) and pluripotent progenitors (Lin-CD34+CD38-CD45RA-CD90-).
Results. It was shown that in patients with hemoblastoses, the relative number of cells with the Lin-CD34+CD38-CD45RA-CD90+ phenotype increases, which corresponds to hematopoietic stem cells, but not pluripotent progenitor cells. At the same time, the number of pluripotent progenitor cells tends to decrease in acute myeloid leukemia.
Conclusions. It was found that in patients with blood cancers, when compared with healthy donors, changes in the subpopulation composition of pluripotent hematopoietic stem cells are observed.
About the authors
Ekaterina Aleksandrovna Pashkina
Federal State Budgetary Scientific Institution "Research Institute of Fundamental and Clinical Immunology", Laboratory of Clinical Immunopathology
Email: pashkina.e.a@yandex.ru
ORCID iD: 0000-0002-4912-5512
PhD, Head of Laboratory
Russian FederationAlina Aleksandrovna Aktanova
Federal State Budgetary Scientific Institution "Research Institute of Fundamental and Clinical Immunology", Laboratory of Clinical Immunopathology
Email: aktanova_al@mail.ru
Junior Research Associate, Laboratory of Clinical Immunopathology
Russian Federation, NovosibirskMaria Vladimirovna Bykova
Federal State Budgetary Scientific Institution "Research Institute of Fundamental and Clinical Immunology", Laboratory of Clinical Immunopathology
Email: maria18021997@mail.ru
Junior Researcher
Russian FederationIvan Pavlovich Skachkov
Federal State Budgetary Scientific Institution "Research Institute of Fundamental and Clinical Immunology", Laboratory of Clinical Immunopathology
Email: ivanskachkov02@gmail.com
Laboratory Assistant
Russian FederationNatalya Viktorovna Pronkina
Federal State Budgetary Scientific Institution "Research Institute of Fundamental and Clinical Immunology", Laboratory of Clinical Immunopathology
Email: fake@neicon.ru
Head of laboratory of clinical immunology,
Russian Federation
Vera Vasilevna Denisova
Federal State Budgetary Scientific Institution "Research Institute of Fundamental and Clinical Immunology", Laboratory of Clinical Immunopathology
Email: verden@bk.ru
PhD, Head of Department
Russian FederationVladimir Aleksandrovich Kozlov
Federal State Budgetary Scientific Institution "Research Institute of Fundamental and Clinical Immunology", Laboratory of Clinical Immunopathology
Author for correspondence.
Email: vakoz40@yandex.ru
PhD, MD (Medicine), Professor, Full Member, Russian Academy of Sciences, Scientific Director
Russian Federation, room 215, 14, Yadrintsevskaya str., Novosibirsk, 630099References
- Zhang, N., Wu, J., Wang, Q. et al. Global burden of hematologic malignancies and evolution patterns over the past 30 years. Blood Cancer J. 13, 82 (2023). https://doi.org/10.1038/s41408-023-00853-3
- Litvitsky P. F., Zhevak T. N. Hemoblastoses. Leukemias of lymphoid origin. Issues of modern pediatrics. 2016; 15: 457–470. doi: 10.15690/vsp.v15i5.1620
- Rugal V. I., Bessmeltsev S. S., Semenova N. Yu., Gritsaev S. V., Kostroma I. I., Enukashvili N. I., Chubar A. V., Ivolgin D. A. (2019). Characteristics of the bone marrow microenvironment in multiple myeloma before and after therapy. Siberian Scientific Medical Journal, 39 (1), 112-118.
- Dander E, Palmi C, D'Amico G, Cazzaniga G. The Bone Marrow Niche in B-Cell Acute Lymphoblastic Leukemia: The Role of Microenvironment from Pre-Leukemia to Overt Leukemia. Int J Mol Sci. 2021 Apr 23;22(9):4426. doi: 10.3390/ijms22094426.
- KW. Christopherson,LA. Paganessi, DR. Rhoades, HM. Dillon,S Gezer, ML. Larson,H C. Fung,S A. Gregory; Abnormally High Levels of Circulating CD34+CD38−, CD34+CD38+, and CD10+ Hematopoietic Stem and Progenitor Cells in the Peripheral Blood of B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Suggest the Presence of Additional Therapeutic Target Cells.. Blood 2007; 110 (11): 4711. doi: https://doi.org/10.1182/blood.V110.11.4711.4711
- Zeijlemaker W, Grob T, Meijer R, Hanekamp D, Kelder A, Carbaat-Ham JC, Oussoren-Brockhoff YJM, Snel AN, Veldhuizen D, Scholten WJ, Maertens J, Breems DA, Pabst T, Manz MG, van der Velden VHJ, Slomp J, Preijers F, Cloos J, van de Loosdrecht AA, Löwenberg B, Valk PJM, Jongen-Lavrencic M, Ossenkoppele GJ, Schuurhuis GJ. CD34+CD38- leukemic stem cell frequency to predict outcome in acute myeloid leukemia. Leukemia 2019 May;33(5):1102-1112. doi: 10.1038/s41375-018-0326-3.
- Reuvekamp, T., Ngai, L.L., den Hartog, D. et al. CD34+CD38- leukemia stem cells predict clinical outcomes in acute myeloid leukemia patients treated non-intensively with hypomethylating agents. Leukemia (2025). https://doi.org/10.1038/s41375-025-02539-0
- Movchan L.V., Shman T.V. ANALYSIS OF THE NUMBER OF CELLS WITH THE PHENOTYPE CD34+CD38- AND CD34+CD38-CD19+ AS POTENTIAL LEUKEMIA STEM CELLS IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA. Health and Ecology Issues. 2011;(2S):66-69. https://doi.org/10.51523/2708-6011.2011-8-2s-22
Supplementary files
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).